AstraZeneca vaults to the front of the Covid-19 vaccine race, teaming up to globalize Oxford candidate
Before last week, AstraZeneca was watching with the rest of the world as researchers at Oxford University’s Jenner Institute began pushing their Covid-19 vaccine in development into the public eye. And then Mene Pangalos, the EVP of biopharma R&D, talked to John Bell, an Oxford professor and longtime friend.
Within days, they sketched the outlines of a collaboration unveiled today that gives AstraZeneca a central role in the global development, manufacturing and distribution of the vaccine — should the Phase I/II results come back positive in the summer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,200+ biopharma pros reading Endpoints daily — and it's free.